Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

May 23, 2022

Study Completion Date

May 31, 2022

Conditions
Chronic Kidney Disease (CKD)Type 2 Diabetes Mellitus (T2DM)Coronary Artery Disease (CAD)
Interventions
DRUG

Clopidogrel

Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.

DRUG

Clopidogrel active metabolite

In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)

Trial Locations (1)

32209

University of Florida Jacksonville, Jacksonville

All Listed Sponsors
collaborator

Scott R. MacKenzie Foundation

OTHER

lead

University of Florida

OTHER

NCT03774394 - Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus | Biotech Hunter | Biotech Hunter